Pparα Ablation Suppresses T Cell Responses and Anti-Tumor Immunity By Compromising the Antigen-Presenting Properties of Tumor-Associated Macrophages
Anthos Christofides(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Carol Cao(Beth Israel Deaconess Medical Center), Rinku Pal(Beth Israel Deaconess Medical Center), Chinmay Jani(Mount Auburn Hospital), Natalia M. Tijaro-Ovalle(Beth Israel Deaconess Medical Center), Halil‐Ibrahim Aksoylar(Beth Israel Deaconess Medical Center), Rushil Shah(Nationwide Children's Hospital), Nikolaos Patsoukis(Beth Israel Deaconess Medical Center), Qi Wang(Jilin University), Eirini Konstantinidou(Beth Israel Deaconess Medical Center)
Cited by 2
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859